WALTHAM, Mass., March 13 Proteon Therapeutics, Inc.(http://www.proteontherapeutics.com), a privately held biopharmaceuticalcompany developing novel, first-in-class pharmaceuticals to address themedical needs of patients with kidney and vascular diseases, has appointedGregory D. Phelps, a seasoned biopharmaceutical executive, to the Company'sBoard of Directors. Mr. Phelps brings more than 30 years of executiveleadership and experience in the medical products and biotechnology industriesto Proteon.
"Greg's extensive experience in leading both large and small biotechnologycompanies through financing and licensing transactions as well as biologicproduct development, approval and launch makes Greg an ideal fit for ourBoard," said Timothy Noyes, Proteon's president and CEO. "We are extremelyfortunate to have attracted someone with Greg's business skills and acumen tothe Proteon Board of Directors."
"I am very pleased to join Proteon's Board of Directors given thesignificant potential for important medical advances based on the Company'stechnology and the strength of the management team and investor group," saidGreg Phelps. "I personally look forward to working closely with the Companyas it pursues its business and product development opportunities."
Gregory D. Phelps' career has been focused for over thirty years in themedical products and biotechnology fields, where he has held Chief ExecutiveOfficer and other executive management positions in several companies. He hasserved as Chief Executive Officer of RenaMed Biologics, Inc., ArdaisCorporation, Viagene, Inc. and ZymoGenetics, Inc. He has also served as ViceChairman of Dyax Corporation, Executive Vice President of Genzyme Corporationand Vice President of Baxter Travenol Laboratories, Inc (now BaxterHealthcare). Mr. Phelps is currently on the Board of Directors of EPIXPharmaceuticals and has previously served on the Boards of Directors of ninepublic and private companies in the health care field, as well as on theBoards of The Hemophilia Foundation of California and the Charles River Schoolof Dover, MA. He holds a B.S. in Electrical Engineering from BradleyUniversity and an MBA from Harvard Business School.
About Proteon Therapeutics
Proteon Therapeutics, Inc., is a privately held biopharmaceutical companydeveloping novel, first-in-class pharmaceuticals to address the critical,rapidly expanding medical needs of patients with kidney and vascular diseases.The company is leveraging a unique understanding of tissue remodeling todevelop a pipeline of proprietary pharmaceuticals. The company isheadquartered in Waltham, MA, and has research facilities in Kansas City, MO.For additional information please visit http://www.proteontherapeutics.com.
SOURCE Proteon Therapeutics, Inc.